The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S16-S20 , July 2010

The Role of Vasodilating β-Blockers in Patients with Complicated Hypertension: Focus on Nebivolol

  • Thomas D. Giles, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Thomas D. Giles, MD, 109 Holly Drive, Metairie, Louisiana 70005

References 

  1. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623–629
  2. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–357
  3. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11:1244–1247
  4. Elliott WJ, Meyer PM. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis. J Clin Hypertens. 2007;9(suppl A):A210
  5. Weber MA. The role of new β-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(pt 2):169S–176S
  6. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269–277
  7. Bermúdez V, Bermúdez F, Acosta G, et al. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition. Am J Ther. 2008;15:326–333
  8. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med. 2008;121:179–184
  9. Wallace SML, Yasmin , McEniery CM, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50:228–233
  10. Gates PE, Boucher ML, Silver AE, Monahan KD, Seals DR. Impaired flow-mediated dilation with age is not explained by l-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. J Appl Physiol. 2007;102:63–71
  11. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002;40:754–760
  12. Kahn DF, Duffy SJ, Tomasiam D, et al. Effects of black race on forearm resistance vessel function. Hypertension. 2002;40:195–201
  13. Taylor AA, Bakris GL. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010;123(suppl):S21–S26
  14. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–1538
  15. Prisant LM, Mensah GA. Use of β-adrenergic receptor blockers in blacks. J Clin Pharmacol. 1996;36:867–873
  16. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  17. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? (A systematic review). JAMA. 1998;279:1903–1907
  18. Douglas JG, Bakris GL, Epstein M, et al. Hypertension in African Americans Working Group Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Arch Intern Med. 2003;163:525–541
  19. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825–831
  20. Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168–1172
  21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914–921
  22. Sheats N, Lin Y, Zhao W, Cheek DE, Lackland DT, Egan BM. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically under-served patients. Ethn Dis. 2005;15:25–32
  23. Rehman SU, Hutchison FN, Hendrix K, Okonofua EC, Egan BM. Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites. Arch Intern Med. 2005;165:1041–1047
  24. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertension drug therapy in black patients. Ann Intern Med. 2004;141:614–627
  25. Wright JT, Bakris G, Greene T, et al. African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431
  26. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinsky T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–3801
  27. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Racial differences in nitric oxide–mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998;31:1235–1239
  28. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Attenuation of cyclic nucleotide–mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:90–95
  29. Lang CC, Stein CM, He HB, et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension. 1997;30:157–162
  30. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707–1713
  31. Kamp O, Sieswerda GT, Visser CA. Comparison of effects of systolic and diastolic left ventricular function on nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–348
  32. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866–875
  33. Dhakam Z, Yasmin , McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351–356
  34. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004;44:305–310
  35. Cleophas TJ, Grabowsky I, Niemeyer MG, Mäkel WM, van der Wall EE, et al. Nebivolol Follow-up Study Group Paradoxical pressor effects of β-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation. 2002;105:1669–1671
  36. Gradman AH. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker–associated adverse events with those of placebo. J Clin Hypertens (Greenwich). 2008;10(suppl A):A120
  37. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 2002;11:182–188
  38. Flather MD, Shibata MC, Coats AJS, et al. SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(10)00340-2

doi: 10.1016/j.amjmed.2010.04.014

The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S16-S20 , July 2010

Article Tools

* Image Usage & Resolution